---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092967"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T12:02:53.694469+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FibroGen cuts 75% of U.S. workforce (127 employees); charges $16-18M

## Summary
- Workforce reduction of ~75% (127 U.S. employees) effective Aug 2, 2024.
- Estimated non-recurring charges of $16-18M for severance, payroll, benefits.
- Majority of charges expected in H2 2024; cash payments substantially complete by Q1 2025.
- Restructuring follows negative pamrevlumab clinical trial data announced earlier that week.
- Potential position eliminations subject to legal requirements; process may extend beyond Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-092967
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017024092967/0000950170-24-092967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017024092967/fgen-20240802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092967
- JSON: https://secwatch.observer/filing/0000950170-24-092967.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092967.txt

## Key facts
- Restructurings & Charges
  KYNTRA BIO, INC. announced a restructuring with charges of $16-18 million affecting U.S. workforce (approximately 75% with 127 U.S. employees).
  - Type: restructuring
  - Charge: $16-18 million
  - Affected area: U.S. workforce
  - Headcount: approximately 75% with 127 U.S. employees
  source text: in the progress we have made, and continue to make, in science and the biotechnology industry. The Company estimates that it will incur non-recurring charges in the range of $16-18 million in connection with the Plan, primarily consisting of severance payments, notice pay, accrued vacation, payroll tax and employee benefits contributions. The Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017024092967/0000950170-24-092967-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.